文 献5）Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res 2015; 43: W460–6.6）Hirai K, Shirai T, Rachi Y, Uehara S, Ueda M, Nakatani E, et al. Impact of gene expression associated with glucocorticoid-induced transcript 1 (GLCCI1) on severe asthma and future exacerbation. Biol Pharm Bull 2019; 42: 1746–52.7）Saito A, Horie M, Nagase T. TGF-β signaling in lung health and disease. Int J Mol Sci 2018; 19: E2460.8）Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med 2019; 381: 1023–34.9）Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2018; 18: 454–66.1401）Sin DD, Miravitlles M, Mannino DM, Soriano JB, Price D, Celli BR, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J 2016; 48: 664–73.2）Shirai T, Hirai K, Gon Y, Maruoka S, Mizumura K, Hikichi M, et al. Combined assessment of serum periostin and YKL-40 may identify asthma-COPD overlap. J Allergy Clin Immunol Pract 2019; 7: 134-145.e1.3）Hirai K, Shirai T, Suzuki M, Akamatsu T, Suzuki T, Hayashi I, et al. A clustering approach to identify and characterize the asthma and chronic obstructive pulmonary disease overlap phenotype. Clin Exp Allergy 2017; 47: 1374–82.4）Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–73.
元のページ ../index.html#154